Duality Biotherapeutics Inc (Ticker: 9606 HK) is a China-based biotechnology company operating in the biomedical/gene industry, focusing on antibody-drug conjugates. Duality Biotherapeutics plans its IPO on the Hong Kong Stock Exchange on April 15, 2025. The company is offering 15.07 million shares, with an indicative price range of HKD 94.60 to HKD 103.20 per share. It aims to raise up to HKD 1.56 billion (approximately USD 200.7 million). The final offer price is expected to be determined on April 11, 2025. Cornerstone investors have reportedly agreed to subscribe for up to USD 65 million worth of shares. Key managers involved in the offering include CICC, BOCI Asia, and CMB International.